EMILIN2

Across TCGA pan-cancer cohorts, EMILIN2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of EMILIN2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EMILIN2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EMILIN2 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where EMILIN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EMILIN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	+1.726	<.001	12	view →
PDAC	Female	All	+0.720	<.001	6	view →
HNSC	All	II,III,IV	−0.236	.002	6	view →
COAD	Female	All	−0.278	<.001	5	view →
LUAD	All	II,III,IV	−0.263	<.001	5	view →
OV	All	All	−0.985	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

EMILIN2–CCRCC

Open the CCRCC breakdown →